Department of Immunotechnology & CREATE Health Translational Cancer Center, Lund University, BMC D13, Lund, Sweden.
Proteomics Clin Appl. 2012 Aug;6(7-8):343-5. doi: 10.1002/prca.201200020.
Despite massive efforts, proteomics has not delivered biomarkers of clinical value. However, the technologies that are emerging today have the power to reach deep into proteomes and identify the patterns associated with different diseases. Study design is then crucial and sample quality, bioinformatics approaches, prevalidation, using independent patient cohort need to attract increased attention before proteomics will contribute to the needs of personalized medicine.
尽管已经付出了巨大努力，但蛋白质组学仍未能提供具有临床价值的生物标志物。然而，如今涌现的技术具有深入蛋白质组并识别与不同疾病相关模式的强大能力。因此，研究设计至关重要，在蛋白质组学能够满足个性化医疗需求之前，需要更加关注样本质量、生物信息学方法、预验证以及使用独立的患者队列。
